Novartis' Kesimpta Goes Up Against Roche's Ocrevus In MS
The anti-CD20 monoclonal antibody was approved by the US FDA for relapsing multiple sclerosis, bringing a new treatment to the crowded therapeutic area – with the benefit of self-administration.
You may also be interested in...
Keeping Track: US FDA Has Clinical Questions For Tricida, Gilead And BioMarin; Enspryng And Winlevi Approved
The latest drug approval and decision news from the Pink Sheet’s US FDA Performance Tracker.
Novartis’s anti-CD20 MS candidate, ofatumumab, shows promise in initial findings from the ASCLEPIOS Phase III studies, but more details are needed to show how it stacks up against Sanofi’s Aubagio, and ultimately against Roche’s Ocrevus.
Mayzent is the first oral therapy proven to delay progression in patients with secondary progressive multiple sclerosis and Novartis pharma chief Paul Hudson tells Scrip its $88,500 list price will not affect access.